The initial generations of EGFR-tyrosine kinase inhibitors, including first-generation agents such as gefitinib, erlotinib, and icotinib, and second-generation TKIs like dacomitinib and afatinib, demonstrated significant systemic activity in EGFR-mutated NSCLC [29,30,31,32]. Here, EGFR is linked to non-small cell lung carcinoma.